Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-25-009098
Filing Date
2025-02-04
Accepted
2025-02-04 16:05:17
Documents
5
Period of Report
2025-03-21

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm253006-2_def14a.htm DEF 14A 156596
2 GRAPHIC lg_markertherapeutics-4clr.jpg GRAPHIC 31700
3 GRAPHIC px_24markerthepy01pg01-4c.jpg GRAPHIC 296447
4 GRAPHIC px_24markerthepy01pg02-4c.jpg GRAPHIC 139746
5 GRAPHIC px_24markerthepy01pg03-4c.jpg GRAPHIC 162862
  Complete submission text file 0001104659-25-009098.txt   990683
Mailing Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021
Business Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

EIN.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37939 | Film No.: 25588108
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)